Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Previously Published Works bannerUC San Diego

Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19.

  • Author(s): Li, Jinghong;
  • Wei, Qi;
  • Li, Willis X;
  • McCowen, Karen C;
  • Xiong, Wei;
  • Liu, Jiao;
  • Jiang, Wenlijun;
  • Marin, Traci;
  • Thomas, Robert L;
  • He, Ming;
  • Gongol, Brendan;
  • Hepokoski, Mark;
  • Yuan, Jason X-J;
  • Shyy, John Y-J;
  • Xiong, Nian;
  • Malhotra, Atul
  • et al.

Published Web Location

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834011/
No data is associated with this publication.
Abstract

Objective

Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear. Metformin increases the expression of angiotensin converting enzyme 2, a known receptor for severe acute respiratory syndrome coronavirus 2. Data from people with T2DM hospitalized for COVID-19 were used to test the hypothesis that metformin use is associated with improved survival in this population.

Methods

Retrospective analyses were performed on de-identified clinical data from a major hospital in Wuhan, China, that included patients with T2DM hospitalized for COVID-19 during the recent epidemic. One hundred and thirty-one patients diagnosed with COVID-19 and T2DM were used in this study. The primary outcome was mortality. Demographic, clinical characteristics, laboratory data, diabetes medications, and respiratory therapy data were also included in the analysis.

Results

Of these 131 patients, 37 used metformin with or without other antidiabetes medications. Among the 37 metformin-taking patients, 35 (94.6%) survived and 2 (5.4%) did not survive. The mortality rates in the metformin-taking group versus the non-metformin group were 5.4% (2/37) versus 22.3% (21/94). Using multivariate analysis, metformin was found to be an independent predictor of survival in this cohort (P = .02).

Conclusion

This study reveals a significant association between metformin use and survival in people with T2DM diagnosed with COVID-19. These clinical data are consistent with potential benefits of the use of metformin for COVID-19 patients with T2DM.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item